+ 1 888 391 5441

Investigation Report on China's Sildenafil Market, 2018-2022

According to statistics, more than 60% of Chinese men aged 35 and above suffer from sexual dysfunction.
Sildenafil is developed by Pfizer to treat penile erectile dysfunction, pulmonary hypertension, mountain sickness, etc. Pfizer's application for Viagra's patent was approved by China's State Intellectual Property Office in 1994. According to the patent law of China, the patent should be valid for 20 years till 2014. After the expiration of the patent, pharmaceutical companies can produce Sildenafil as long as they have obtained the approval. Therefore, Chinese manufacturers began to launch Sildenafil in 2014. CRI's market investigation shows that China's Sildenafil market is dominated by Pfizer's Viagra, Baiyunshan's Jinge and Yabang Aipusen's Wanfeile. The market share of Pfizer's Viagra, either by sales volume or by sales value, exceeded 90% in 2017. However, it will decrease as China-made counterparts are launched.
The number of erectile dysfunction patients will continue to rise in the next few years as the economy develops, the lifestyle changes, and psychological pressures increase in China. Furthermore, Sildenafil is becoming more affordable with the rise of income in China. The sales value of Sildenafil exceeded CNY 30 million in 2017, and the market will continue to grow in the next few years.

Topics Covered:
- Development environment of China's Sildenafil market
- Sales of Sildenafil in China
- Competition pattern of China's Sildenafil market
- Prices of Sildenafil in China's Hospitals
- Driving forces and market opportunities for China's Sildenafil market
- Prospect of China's Sildenafil market
Why http://www.chinamarketresearchreports.com

Investigation Report on China's Sildenafil Market, 2018-2022


Related reports :

Avail 15% Discount, Use JUNE15 Coupon Code

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy